Media
Op-ed: How equitable access to medicines can drive sustainable returns for investors
19 November 2024
Date
20 November 2024
Japanese companies struggle due to limited geographical reach
A recent article by pharmaceutical-focused media outlet Yakuji Nippo covers the Access to Medicine Foundation's recently released report, which evaluates large pharmaceutical companies on their efforts to expand access in low- and middle-income countries (LMICs). The article focuses specifically on the Foundation’s analyses of the four Japanese companies included in the analysis.
Direct links
The outlet spoke with Camille Romero, the Foundation’s Research Programme Manager and Marjin Verhoef, Director of Operations and Government Relations, about the results of the 2024 Access to Medicine Index, with the conversation focusing the results related to the four Japanese companies included: Takeda, Eisei, Astellas and Daiichi Sankyo.
It highlights that of the four Japanese companies, Takeda ranked the highest at number nine, due to its integrated drug access strategy and market plan for target countries in its clinical pipeline. However, the three other companies ranked in the last five slots, underlining the need for improvement by these companies in their access-to-medicine efforts in LMICs.
The article also relays the key recommendations for pharmaceutical companies from the report, including increased efforts by pharmaceutical companies in expanding geographic presence of clinical trials, improvements in licensing and engaging in technology transfers.
